{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Netherlands Healthcare news", "home_page_url": "https://sharemaestro.com/newsreel/nl/healthcare/", "feed_url": "https://sharemaestro.com/newsreel/nl/healthcare/feed.json", "description": "Latest Healthcare company headlines from Netherlands, newest first, with industry sections, source links and company research.", "language": "en", "items": [{"id": "source:2119559983d88f54fed2f9b6de7ae9cd6c9c03584d4dbac9d637eb5c0a7d098a", "url": "https://finance.yahoo.com/healthcare/articles/philips-enxtam-phia-expands-open-001645833.html", "external_url": "https://finance.yahoo.com/healthcare/articles/philips-enxtam-phia-expands-open-001645833.html", "title": "Philips (ENXTAM:PHIA) Expands Open Monitoring Ecosystem And Launches Postpartum Support Tool", "content_text": "Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Koninklijke Philips (ENXTAM:PHIA) announces new collaborations to expand its open monitoring ecosystem and connected care offerings. The company introduces the Philips Avent Share the Care Connector to support postpartum mothers with digital tools and guidance. Philips works with health technology partners to extend continuous and out of hospital patient monitoring capabilities. The Share the Care Connector is launched in co", "date_published": "2026-08-14T00:16:45+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Guidance", "PHIA"], "_sharemaestro": {"country": "Netherlands", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PHIA", "name": "Koninklijke Philips N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/f5d65c14-5961-4b67-938f-c2b1ed497d07/"}]}}, {"id": "source:244e49ff005a068ab08a7c98d6917683f94fa19dc5eb742699689f75b3548f59", "url": "https://finance.yahoo.com/markets/stocks/articles/koninklijke-philips-enxtam-phia-following-171103976.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/koninklijke-philips-enxtam-phia-following-171103976.html", "title": "Koninklijke Philips (ENXTAM:PHIA) Following Exor Stake Update Still Looks Close To Fair Value", "content_text": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Koninklijke Philips (ENXTAM:PHIA) has drawn renewed attention after updating its long-term agreement with Exor. The move allows Exor to raise its shareholding to 22%, while existing governance arrangements remain unchanged. See our latest analysis for Koninklijke Philips. At a share price of \u20ac23.19, Koninklijke Philips has seen a small pullback over the past month with a 1 month share price return of a 3.74% decline, although the 3 year total shareholder return of 31.21% points to a stro", "date_published": "2026-08-13T17:11:03+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PHIA"], "_sharemaestro": {"country": "Netherlands", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PHIA", "name": "Koninklijke Philips N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/f5d65c14-5961-4b67-938f-c2b1ed497d07/"}]}}, {"id": "source:ca9eb134e34c73a716cbd67a99ab16c1949dc68ce7a59305eb2c3ec2e4403289", "url": "https://finance.yahoo.com/technology/articles/philips-shell-targeted-hacking-group-160630644.html", "external_url": "https://finance.yahoo.com/technology/articles/philips-shell-targeted-hacking-group-160630644.html", "title": "Philips, Shell targeted by hacking group", "content_text": "AMSTERDAM, Aug 13 (Reuters) - Philips and Shell were recently targeted by Cl0p, the hacking group said in \u200ca statement on its website. Philips said it had \u200cbeen targeted by Cl0p while Shell said it was aware of a \u200brecent \"possible incident\", confirming an earlier report by Dutch media outlet BNR. \"We are working with our security teams and relevant experts to investigate the situation,\" a Shell spokesperson said. \"Philips has \u200cidentified and contained \u2060an attempted cybersecurity compromise of a specific enterprise server related to internal data,\" Philips said \u2060in a statement, adding that the ", "date_published": "2026-08-13T16:06:30+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "PHIA"], "_sharemaestro": {"country": "Netherlands", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PHIA", "name": "Koninklijke Philips N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/f5d65c14-5961-4b67-938f-c2b1ed497d07/"}]}}, {"id": "source:d9f58c9bf0b10a0fadf326e5dabcd38376939a4346db8c1bb34e6b57eb2ee83c", "url": "https://www.nasdaq.com/articles/pharming-launches-joenja-japan-apds", "external_url": "https://www.nasdaq.com/articles/pharming-launches-joenja-japan-apds", "title": "Pharming Launches Joenja In Japan For APDS", "content_text": "(RTTNews) - Pharming Group (PHAR) announced the commercial launch of Joenja (leniolisib) in Japan for adult and children aged 4 years and older with activated PI3K delta syndrome, following its inclusion in NHI price list. Activated PI3K delta syndrome (APDS) is a rare primary immunodeficiency caused by genetic variants in the PI3Kd (phosphoinositide 3-kinase delta) pathway, leading to recurrent infections, immune dysregulation, and increased risk of lymphoma. Joenja (leniolisib), and oral PI3Kd inhibitor, was approved based on results from a randomized, placebo-controlled Phase III trial that", "date_published": "2026-08-13T07:15:18+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Market update", "PHARM"], "_sharemaestro": {"country": "Netherlands", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PHARM", "name": "Pharming Group N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/a798bff4-517d-40b4-abac-a12327c0866c/"}]}}, {"id": "source:80a3b3777dc5d07225ba54fc3f7383d138d1d08013792e57a78293fc81738015", "url": "https://finance.yahoo.com/healthcare/articles/ai-enabled-imaging-modalities-market-112700624.html", "external_url": "https://finance.yahoo.com/healthcare/articles/ai-enabled-imaging-modalities-market-112700624.html", "title": "AI-Enabled Imaging Modalities Market Report: Evaluating AI Software Integration, FDA Approvals, and Competitive Strategies of GE HealthCare, Canon, Siemens, and Philips", "content_text": "Company Logo Accelerating clinical adoption highlighted by GE HealthCare's latest FDA clearance for AI-guided radiation planning, Canon Medical's AI deep-learning CT launch, and strong 2026 order books across Siemens Healthineers and Philips is transforming diagnostic workflows globally. This study delivers an in-depth competitive analysis, technology roadmap, and regional forecasts across MRI, CT, X-ray, Ultrasound, and PET modalities. AI-Enabled Imaging Modalities MarketAI-Enabled Imaging Modalities Market Dublin, Aug. 12, 2026 (GLOBE NEWSWIRE) -- The \"AI-Enabled Imaging Modalities Market - ", "date_published": "2026-08-12T11:27:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "PHIA"], "_sharemaestro": {"country": "Netherlands", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PHIA", "name": "Koninklijke Philips N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/f5d65c14-5961-4b67-938f-c2b1ed497d07/"}]}}, {"id": "source:4d2e178044b7f8ce040de8c6656f07deff97997333471c1d03a1caa5b7cad06f", "url": "https://finance.yahoo.com/markets/stocks/articles/1-semiconductor-stock-long-term-060522696.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/1-semiconductor-stock-long-term-060522696.html", "title": "1 Semiconductor Stock for Long-Term Investors and 2 Facing Challenges", "content_text": "1 Semiconductor Stock for Long-Term Investors and 2 Facing Challenges Semiconductors are the silicon backbone of the digital revolution. The amount of data we ingest is also increasing exponentially, leading to elevated demand for chips with more processing power. This secular trend bodes well for the industry, which has posted a six-month gain of 50.2% and beaten the S&P 500 by 39.1 percentage points. Although these businesses have produced results lately, investors should tread carefully as not all companies are equipped for the next technological innovation. On that note, here is one semico", "date_published": "2026-08-12T06:05:22+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PHIA"], "_sharemaestro": {"country": "Netherlands", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PHIA", "name": "Koninklijke Philips N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/f5d65c14-5961-4b67-938f-c2b1ed497d07/"}]}}, {"id": "source:931caa2ad66799ec95a108f37ebe2326c7f2d5b8f3a0f784ace0a25ae4da0353", "url": "https://finance.yahoo.com/markets/stocks/articles/investors-buy-inogen-low-valuation-162200792.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/investors-buy-inogen-low-valuation-162200792.html", "title": "Should Investors Buy Inogen as Low Valuation Meets Execution Risk?", "content_text": "Inogen, Inc. INGN trades at a steep sales-multiple discount even as second-quarter 2026 margins improved and international demand remained firm. The disconnect creates an interesting setup, but the operating recovery is not yet broad-based. Investors must weigh better cost control, expanding respiratory offerings and a debt-free balance sheet against persistent pressure in U.S. direct sales and rentals. That mix supports patience rather than a simple value-driven call. Inogen, Inc Price and ConsensusInogen, Inc Price and Consensus Inogen, Inc price-consensus-chart | Inogen, Inc Quote Inogen's ", "date_published": "2026-08-11T16:22:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PHIA"], "_sharemaestro": {"country": "Netherlands", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PHIA", "name": "Koninklijke Philips N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/f5d65c14-5961-4b67-938f-c2b1ed497d07/"}]}}, {"id": "source:d56bac5c876b80aeeca49e31e5dfbdb723366f1c47826404898c7d2ffbcfb38b", "url": "https://www.nasdaq.com/articles/royal-philips-and-exor-update-long-term-relationship-agreement", "external_url": "https://www.nasdaq.com/articles/royal-philips-and-exor-update-long-term-relationship-agreement", "title": "Royal Philips And Exor Update Long-Term Relationship Agreement", "content_text": "(RTTNews) - Royal Philips (PHG), a health technology company, and Exor N.V., an investment company, announced that they have agreed to update their long-term relationship agreement. Royal Philips provides image-guided therapy, diagnostic imaging, ultrasound, monitoring, and enterprise informatics and made approximately 18 billion euros in sales in 2025. Exor is the largest shareholder in companies including Ferrari, Philips, CNH and Stellantis. In August 2023, Royal Philips and Exor entered into a relationship agreement, under which Exor bought a 15% shareholding in Royal Philips to provide co", "date_published": "2026-08-11T08:14:10+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Market update", "PHIA"], "_sharemaestro": {"country": "Netherlands", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PHIA", "name": "Koninklijke Philips N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/f5d65c14-5961-4b67-938f-c2b1ed497d07/"}]}}, {"id": "source:8ccfd82f3f641119acb1c918e4d22305dabd7bfabd79ea48f63f1f1e36da81e5", "url": "https://finance.yahoo.com/healthcare/articles/exor-philips-extend-long-term-060000415.html", "external_url": "https://finance.yahoo.com/healthcare/articles/exor-philips-extend-long-term-060000415.html", "title": "Exor and Philips Extend Long-term Relationship Agreement", "content_text": "Royal Philips Clinician and patient with Azurion and IntraSightClinician and patient with Azurion and IntraSight Exor logoExor logo Disney themes incorporated into Philips Ambient Experience for MRIDisney themes incorporated into Philips Ambient Experience for MRI Nurses at central monitoring stationNurses at central monitoring station August 11, 2026 Amsterdam, the Netherlands - Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Exor N.V. today announced that they have agreed to update their long-term relationship agreement. It provides Exor with the flexibility to increase its shareholding in Philips to up to 22% of the company's issued ordinary share capital and voting rights, up from the previous 20% cap, with the possibility of increasing its stake further subject to approval by the Philips Supervisory Board. Governance arrangements remain unchanged, including Exor's right to nominate one member of the Philips Supervisory Board. Feike Sijbesma, Chairman of the Supervisory Board of Royal Philips, said: \"Exor's long-term commitment underlines its confidence in Philips and its strategy. The Supervisory Board values Exor's constructive engagement, and I appreciate Beno\u00eet Ribadeau-Dumas' continued contribution as we oversee Philips' strategic direction.\" Roy Jakobs, CEO of Royal Philips, said: \"The updated agreement reflects Exor's support for Philips and its Board of Management as we execute our 2026\u20132028 plan. It underscores the value creation potential of the plan and our focus on delivering profitable growth.\" John Elkann, CEO of Exor, said: \"We support Philips' long-term strategy defined by innovation, value creation and disciplined execution. The updated agreement reflects our continued commitment to Philips as its largest shareholder.\" About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in image-guided therapy, diagnostic imaging, ultrasound, monitoring, enterprise informatics and personal health. Philips generated 2025 sales of approximately EUR 18 billion and employs approximately 63,700 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter. About Exor Exor N.V. (AEX: EXO) has been building great companies since its foundation by the Agnelli Family. For more than a century, Exor has made successful investments worldwide, applying a culture that combines entrepreneurial spirit and financial discipline. Its portfolio is principally made up of companies in which Exor is the largest shareholder including Ferrari, Philips, CNH and Stellantis. Story Continues Forward-looking statements and other important information This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips' organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements. Media contacts Michael Fuchs Philips Global External Relations Contact details Tel: +31614869261 media@philips.com Dorin Danu Philips Investor Relations Con", "date_published": "2026-08-11T06:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "PHIA"], "_sharemaestro": {"country": "Netherlands", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PHIA", "name": "Koninklijke Philips N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/f5d65c14-5961-4b67-938f-c2b1ed497d07/"}]}}, {"id": "source:14d7d7244743d754207489f3c0d84b2eb7c59374518dcaa3debc8019ec76aa58", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxQLXJ3ZG9TdXJMVVlWRk9ZNkZxd1dfaWV4TS1fa3RFVjM5aFZjUEdBQVdGNE9wdXYxXzAzY1lPejJjMXNTNHlibF9zV2xoS0lPVU9MRUtVVzlTQS1DWXJyaUV3SHd1OUZVYl9PWExKTklfeWV1Z3NOVW40X0w1Zm83WnlWakRhSjNNVGx0OS0xSjBmMjQyTTh1aC1ndHQzWkZJVTdzdUs1anpqeWZqQlp3RXhrM3gzSlBkYjJrYWpveTZiYjVIVWY0N2xJdEZSUmdFSEItd21ZZUFxUldLQ2ZfRmVDdUVyUi1G?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxQLXJ3ZG9TdXJMVVlWRk9ZNkZxd1dfaWV4TS1fa3RFVjM5aFZjUEdBQVdGNE9wdXYxXzAzY1lPejJjMXNTNHlibF9zV2xoS0lPVU9MRUtVVzlTQS1DWXJyaUV3SHd1OUZVYl9PWExKTklfeWV1Z3NOVW40X0w1Zm83WnlWakRhSjNNVGx0OS0xSjBmMjQyTTh1aC1ndHQzWkZJVTdzdUs1anpqeWZqQlp3RXhrM3gzSlBkYjJrYWpveTZiYjVIVWY0N2xJdEZSUmdFSEItd21ZZUFxUldLQ2ZfRmVDdUVyUi1G?oc=5", "title": "RBC stelt prognose Philips bij na resultaten tweede kwartaal; Sector Perform-advies gehandhaafd", "content_text": "RBC stelt prognose Philips bij na resultaten tweede kwartaal; Sector Perform-advies gehandhaafd", "date_published": "2026-07-31T10:35:24+00:00", "authors": [{"name": "MarketScreener Nederland"}], "tags": ["Market update", "PHIA"], "_sharemaestro": {"country": "Netherlands", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PHIA", "name": "Koninklijke Philips N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/f5d65c14-5961-4b67-938f-c2b1ed497d07/"}]}}, {"id": "source:59021b4e1e561671d0ccd836e93f18b938cd9878fcbfc7478506c6d16f8492b4", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNQl84azZSa281dC1SaThtZ3M2ZFVkTTFWVGlRNWtwcDF0WlZBczl6djVsR3RfWWlpbGl5VlFtTU5YV1NZdGdJU1UtTDZxOW1lZGxqMlN2bkppblJKNzBJWERiRHo0TG93YTFYdjRqTHBRTmVubi16ZU5nR3V0WTlvQUNFNTRSZw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNQl84azZSa281dC1SaThtZ3M2ZFVkTTFWVGlRNWtwcDF0WlZBczl6djVsR3RfWWlpbGl5VlFtTU5YV1NZdGdJU1UtTDZxOW1lZGxqMlN2bkppblJKNzBJWERiRHo0TG93YTFYdjRqTHBRTmVubi16ZU5nR3V0WTlvQUNFNTRSZw?oc=5", "title": "Pharming Group N.V.: Fundamentele analyse en financi\u00eble beoordelingen | PHARM | NL0010391025", "content_text": "Pharming Group N.V.: Fundamentele analyse en financi\u00eble beoordelingen | PHARM | NL0010391025", "date_published": "2021-05-08T23:24:30+00:00", "authors": [{"name": "MarketScreener Nederland"}], "tags": ["Market update", "PHARM"], "_sharemaestro": {"country": "Netherlands", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PHARM", "name": "Pharming Group N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/a798bff4-517d-40b4-abac-a12327c0866c/"}]}}, {"id": "source:dcaa96e3ebb1ca412618968f722645c8a50196d38bc655a49053ebfd386cd380", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPTWl2Q1E4RWpabXpvUlVYclZTNE11emQ2U2pRMzIweGZRWEIzWFZRMmRkMFpFRnUzNjVoUDcwbmhTbmNuVV9zSkdXUDJiRzVZX1BWVnRuSHNqMkpTWS03MExlMEQtNGdHVDBsREZEYktDYzdzUHlSTFE5by1sbms5bW9GTGEzcWxuTGVIakg1T2RvckU?oc=5", "external_url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPTWl2Q1E4RWpabXpvUlVYclZTNE11emQ2U2pRMzIweGZRWEIzWFZRMmRkMFpFRnUzNjVoUDcwbmhTbmNuVV9zSkdXUDJiRzVZX1BWVnRuSHNqMkpTWS03MExlMEQtNGdHVDBsREZEYktDYzdzUHlSTFE5by1sbms5bW9GTGEzcWxuTGVIakg1T2RvckU?oc=5", "title": "Vivoryon Therapeutics N.V.: koersdoel en analistenconsensus | VVY | NL00150002Q7", "content_text": "Vivoryon Therapeutics N.V.: koersdoel en analistenconsensus | VVY | NL00150002Q7", "date_published": "2021-05-06T07:48:48+00:00", "authors": [{"name": "MarketScreener Nederland"}], "tags": ["Market update", "VVY"], "_sharemaestro": {"country": "Netherlands", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VVY", "name": "Vivoryon Therapeutics N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/ed225238-5523-4d1f-bb4d-bfcdc7607388/"}]}}]}